BridgeBio Pharma, Inc. (BBIO) stock experienced a significant plummet of 5.71% in the pre-market trading session on Tuesday, February 25th, 2025.
The biopharmaceutical company's stock price drop was primarily driven by its announcement of a $500 million private offering of convertible senior notes due in 2029. BridgeBio plans to use a portion of the net proceeds from the offering to repay all outstanding borrowings under its existing loan agreement with lenders and Blue Owl Corporation. Additionally, the company intends to use up to $50 million of any remaining proceeds to repurchase its common stock from the convertible bond purchasers, with the rest allocated for general corporate purposes.
The convertible debt offering, which could potentially dilute existing shareholders, appears to have contributed to the pre-market decline in BridgeBio's stock price. However, the company's recent fourth-quarter revenue beat, driven by strong sales of its rare heart disease drug Attruby (Beyonttra in the EU), may provide some optimism for investors.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。